Бавуналимаб

Rec. INN (наименование, зарегистрированное ВОЗ)

immunoglobulin half-IG G1-kappa/scFv-h-CH2-CH3, anti-[Homo sapiens LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)] and anti-[Homo sapiens CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)], monoclonal antibody, bispecific;
gamma1 heavy chain anti-LAG3 (1-450) [VH (Mus musculus IGHV6-6*01 (88.0%) -(IGHD) - IGHJ1*01 (93.8%)/ Homo sapiens IGHV3-72*01 (81.0%) -(IGHD) -IGHJ6*01 (86.0%)) CDR-IMGT [8.10.12] (26-33.51-60.99-110) (1-121) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 N114>D (212) R120>K (218) (122-219), hinge 1-15 (221-234), CH2 E1.4,L1.3>P (237), L1.2>V (238), G1.1>A (239), S29>K (270), Q84.2>E (298) (235-343), CH3 E12 (359), M14 (361), L24>D (375), K26>S (377), N44>D (387), Q97>E (421), N100>D (424), M107>L (431), N114>S (437) (344-448), CHS (449-450)) (122-450)], (224-218')-disulfide with kappa light chain anti-LAG3 (1'-218') [V-KAPPA (Mus musculus IGKV3-4*01 (82.8%) -(IGHD) -IGKJ4*01 (100%)/Homo sapiens IGKV1-39*01 (82.8%) -IGKJ2*02 (90.9%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112’-218’)];
IG scFv-h-CH2-CH3 single chain, anti-CTLA4 (1''-477'') [scFv VH-V-kappa anti-CTLA4 1''-246'') [VH (Homo sapiens IGHV3-21*01 (91.8%) -(IGHD) -IGHJ3*01 (92.9%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1''-118'') -20-mer tetrakis(glycyl-lysyl-prolyl-glycyl-seryl) linker (119''-138'') -V-KAPPA (Homo sapiens IGKV3-20*01 (97.9%) -IGHJ1*01 (100%)) CDR-IMGT [7.3.9] (165-171.189-191.228-236) (139''-246'')] -Homo sapiens IGHG1*03 h-CH2-CH3, nG1m1 (247''-477'') [hinge 1-15 C5>S (251) (247-261) -CH2 E1.4,L1.3>P (264), L1.2>V (265), G1.1>A (266), S29>K (297) (262-370),CH3 E12 (386), E13>Q (387), M14 (388), S20>K (394), M107>L (458), N114>S (464) (371-475), CHS (476-477)]];
dimer (230-257'':233-260'')-bisdisulfide, produced in Chinese Hamster Ovary (CHO)-S cell line, glycoform alfa

Поделиться этой страницей